Chardan raised the firm’s price target on Intellia Therapeutics (NTLA) to $91 from $88 and keeps a Buy rating on the shares. The company presented “impressive” data from ATTR patients treated with nex-z in Phase I, demonstrating durable effects on clinical metrics and biomarkers beyond TTR reduction in both patient subsets, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $60 from $70 at Oppenheimer
- Intellia Therapeutics price target lowered to $55 from $76 at Barclays
- Intellia Therapeutics Reports Q3 2024 Financial Progress
- Intellia Therapeutics price target lowered to $40 from $41 at JonesResearch
- Intellia Therapeutics reports Q3 EPS ($1.34), consensus ($1.39)